Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Annona cherimola extract is a botanical research compound derived from the seeds and other parts of the *Annona cherimola* Mill. plant, commonly known as cherimoya. The extract is characterized by its content of bioactive Annonaceous acetogenins (ACGs), which are potent secondary metabolites known to inhibit mitochondrial complex I. Preclinical studies have demonstrated that the extract possesses significant anti-cancer properties, particularly against acute myeloid leukemia (AML) and head and neck cancer cell lines. Its mechanism of action involves the induction of apoptosis through both intrinsic and extrinsic pathways, often associated with the upregulation of pro-apoptotic proteins such as BAX. Despite its potential therapeutic efficacy, the extract's development is constrained by reports of neurotoxicity and genotoxicity linked to its acetogenin components. It is currently a subject of academic investigation and is not an approved pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on annona cherimola extract.